Pembrolizumab, Entinostat
Melanoma, Non-small Cell Lung Cancer, Mismatch Repair-Proficient Colorectal Cancer
Completed
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
―